1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc.

AOXG
Aoxing Pharmaceutical Company, Inc.US flagOther OTC
0.00
USD
- -
- -
320,107.00Market Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
4.84
5.38
- -
0.1
0.29
0.22
0.13
0.14
0.16
0.22
0.26
0.4
0.44
0.4
Basic EPS, GAAP
-0.96
-1.4
-0.08
-0.19
0.15
-0.06
-0.02
-0.16
-0.32
-0.34
-0.16
0.09
0.03
-0.02
Free Cash Flow per Basic Share
-0.6
-0.47
-0.04
-0.11
-0.1
-0.07
-0.13
-0.09
-0.04
-0.18
-0.16
0.01
-0.01
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-21.65
-21.83
-0.14
-0.34
-0.5
-0.36
-0.34
-0.49
-0.79
-1.12
-1.28
-0.92
-0.76
-0.73
Tangible Book Value per Share
20.59
18.11
0.23
0.61
0.19
0.1
0.3
0.31
0.26
0.08
-0.09
0.15
0.22
0.21
Basic Weighted Avg Shares
- -
- -
20
20
25
41
46
47
49
50
50
63
74
76
Sales/Revenue/Turnover
1
1
- -
2
7
9
6
7
8
11
13
25
32
30
Operating Margin (%)
-12.6
-6.57
- -
-151.63
-50.66
-28.42
-58.6
-73
-14.14
-60.47
-26.18
34.13
19.26
3.21
Depreciation Expense
- -
- -
- -
2
1
1
1
1
1
1
1
1
1
1
Net Income, GAAP
- -
- -
-2
-4
4
-2
-1
-7
-16
-17
-8
5
2
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
22.26
114.18
Profit Margin (%)
-19.9
-26
- -
-200.12
51.62
-27.42
-13.61
-111.42
-194.49
-155.17
-64.49
21.56
6.38
-4.86
Working Capital
- -
- -
-5
-10
-13
-18
-5
-7
-9
-10
-23
-20
-11
-9
LT Debt
- -
- -
8
7
8
8
6
4
3
13
8
1
- -
- -
Total Equity
5
5
5
12
25
25
34
36
21
5
-4
10
18
18
Return on Invested Capital (%)
- -
- -
- -
- -
-10.18
- -
- -
- -
- -
- -
- -
- -
11.26
- -
Return on Capital (%)
- -
- -
- -
- -
95.62
- -
- -
- -
- -
- -
- -
- -
-6.32
-6.61
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'17
Dec'17
Mar'17
ST Debt
25
24
28
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
76
76
Market Capitalization
42
24
31

Working Capital

FRC

•

in mil. unless spec.
Sep'17
Dec'17
Mar'17
Total Current Assets
30
31
35
Cash, Cash Equivalents & STI
7
7
7
Accounts Receivable, Net
13
13
15
Inventories
2
2
2
Total Current Liabilities
40
41
44
Payables & Accruals
13
15
15
ST Debt
25
24
28
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-26.01%
-115.55%
79.63%
Free Cash Flow
15.75%
-28.75%
-303.74%
Net Income, GAAP
35.89%
-32.16%
-62.49%
Sales/Revenue/Turnover
- -
39.99%
26.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
5
6
7
8
25
2016
9
8
7
9
32
2017
8
8
6
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
0.01
0.01
- -
0.09
2016
0.02
0.03
0.01
- -
0.03
2017
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Zhenjiang Yue
Full Time Employees
346
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
No. 2 Bojin Mansion Shijiazhuang People's Republic of China
IPO Date
Feb 21, 2005
CIK
0001060426
Website
axzyen.icm.cn
Similar Companies
Bliss GVS Pharma Limited (BLISSGVS.BO)
Apeloa Pharmaceutical Co.,Ltd (000739.SZ)
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY)
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
InnoPharmax Inc. (4172.TWO)
Kilitch Drugs (India) Limited (KILITCH.BO)
Business
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company primarily engaged in the research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products. Its main products include prescription drugs such as Tilidine hydrochloride, Zhongtong'an (an herbal extraction capsule for oral and dental pain), Humifuse Euphorbia Herb Tablet, and Yiqi Qiangshen Granule, an over-the-counter (OTC) herbal extraction for tonifying qi, empowering the body, and promoting blood circulation. Additional product lines cover a wide array of narcotic analgesics and traditional Chinese medicine formulations addressing pain and other health conditions. The company operates mainly in the People's Republic of China and is headquartered in Shijiazhuang, China. It holds approximately 140 drug production certificates encompassing narcotic pain-management, prescription, OTC, and active pharmaceutical ingredient (API) products. Recent strategic developments include clinical trials completion for several products such as oxycodone and acetaminophen tablets and capsules for acute and chronic pain, Buprenorphine/Naloxone sublingual tablets for opioid dependence, and Tilidine/Naloxone compound capsules in Phase II trials for pain treatment. The company maintains strategic alliances with American Oriental Bioengineering, QRxPharma Limited, and other pharmaceutical entities to commercialize narcotic and pain management products for domestic and international markets. Aoxing Pharmaceutical was founded in 2002 and remains focused on working closely with the Chinese government and the State Food and Drug Administration (SFDA) to ensure the regulated availability of its narcotic and pain medicines throughout China. The company underwent a name change from China Aoxing Pharmaceutical Company, Inc. to its current name in 2010 and has been involved recently in corporate reorganizations driven by investments from entities such as Ruijitang Chinese Medicine to strengthen its commercial structure and operations.